Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer

Zheng, Yue; Fu, Yang; Wang, Peipei; Ding, Zhenyu

doi:10.1155/2022/8270305

Cited by 22 publications

(6 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another clinical trial also proposed that autologous transfer of HLA‐C*08:02‐restricted KRAS G12D‐reactive polyclonal CD8 + T‐cell populations successfully cured patients with metastatic CRC 105 . These studies indicate the promise of neoantigen‐specific T cells in CRC therapy 106 …”

Section: The Neoantigen‐based Therapy In Crcmentioning

confidence: 94%

Personalised neoantigen‐based therapy in colorectal cancer

Zhu,

Li,

Chen

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

Colorectal cancer (CRC) has become one of the most common tumours with high morbidity, mortality and distinctive evolution mechanism. The neoantigens arising from the somatic mutations have become considerable treatment targets in the management of CRC. As cancer‐specific aberrant peptides, neoantigens can trigger the robust host immune response and exert anti‐tumour effects while minimising the emergence of adverse events commonly associated with alternative therapeutic regimens. In this review, we summarised the mechanism, generation, identification and prognostic significance of neoantigens, as well as therapeutic strategies challenges of neoantigen‐based therapy in CRC. The evidence suggests that the establishment of personalised neoantigen‐based therapy holds great promise as an effective treatment approach for patients with CRC.

show abstract

Section: The Neoantigen‐based Therapy In Crcmentioning

confidence: 94%

Personalised neoantigen‐based therapy in colorectal cancer

Zhu,

Li,

Chen

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…[ 24 ] Some neoantigens have high specificity and immunogenicity and may be potential targets for immunotherapy. [ 25 ] Scientists hypothesized in the 1980s and 1990s that tumor‐specific antigens (TSAs) such as neoantigens could be presented on the surface of tumor cells by HLA class I to recognize by effector T cells providing anti‐tumor responses and tumor cells elimination. [ 26 ] Due to the high cost of traditional methods for identifying the mutated genes and tumor‐derived neoantigens, it is easier and more economical to use whole‐genome sequencing (WGS) and whole‐exon sequencing (WES) methods.…”

Section: Neoantigensmentioning

confidence: 99%

Neo‐Antigen‐Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach

Chen,

Kong,

Lin

2023

Global Challenges

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second most common malignancy in women and the third most frequent cancer in men. Evidence has revealed that the survival of patients with metastatic CRC is very low, between one and three years. Neoantigens are known proteins encoded by mutations in tumor cells. It is theorized that recognizing neoantigens by T cells leads to T cell activation and further antitumor responses. Neoantigen‐reactive T cells (NRTs) are designed against the mentioned neoantigens expressed by tumor cells. NRTs selectively kill tumor cells without damage to non‐cancerous cells. Identifying patient‐specific and high immunogen neoantigens is important in NRT immunotherapy of patients with CRC. However, the main challenges are the side effects and preparation of NRTs, as well as the effectiveness of these cells in vivo. This review summarized the properties of neoantigens as well as the preparation and therapeutic outcomes of NRTs for the treatment of CRC.

show abstract

“…During the chemotherapy and targeted therapy, the tumor cells often occur new mutations, including reversion mutation, contributing to drug resistance. Many reversions are predicted to encode tumor-specific neoantigens, offering a potential strategy for combating resistance with CAR-T cell therapies, immune checkpoint inhibitors or anti-cancer vaccines [ 270 , 442 , 443 ].…”

Section: Introductionmentioning

confidence: 99%

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells

Li,

Xiao,

Wang

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Recent advances in neoantigen research have accelerated the development of tumor immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody-based therapies, particularly for solid tumors. With the development of next-generation sequencing and bioinformatics technology, the rapid identification and prediction of tumor-specific antigens (TSAs) has become possible. Compared with tumor-associated antigens (TAAs), highly immunogenic TSAs provide new targets for personalized tumor immunotherapy and can be used as prospective indicators for predicting tumor patient survival, prognosis, and immune checkpoint blockade response. Here, the identification and characterization of neoantigens and the clinical application of neoantigen-based TCR-T immunotherapy strategies are summarized, and the current status, inherent challenges, and clinical translational potential of these strategies are discussed.

show abstract

Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer

Cited by 22 publications

References 91 publications

Personalised neoantigen‐based therapy in colorectal cancer

Personalised neoantigen‐based therapy in colorectal cancer

Neo‐Antigen‐Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells

Contact Info

Product

Resources

About